Pfizer shares zoom nearly 9% after marketing and supply agreement with Mylan Pharmaceuticals
Pfizer zoomed 8.6% to a high of Rs 4,448.35 on the BSE today after the company on Friday announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals.
This agreement is regarding the sales and marketing of two brands of the company (Pfizer), Ativan and Pacitane.
“Pursuant to the Regulation 30 of the Listing Regulations, we hereby inform that, the Board of Directors of the Company at their Meeting held today, that commenced on February 20, 2025 at 11.00 a.m. and concluded on February 21, 2025 at 1.45 p.m have approved a proposal today, to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited (“Mylan”) for Marketing and Sale of two brands of the Company, viz., Ativan and Pacitane,” the company said in a regulatory filing.
The announcement was made by the company during market hours on Friday, however, the stock price ended up going down, to close at Rs 4,094.55 on the BSE.
Pfizer also informed that this agreement has been made for a period of 5 years and within the Indian territory.
Stock Trading
Maximise Returns by Investing in the Right Companies
By — The Economic Times, Get Certified By India's Top Business News Brand
Stock Trading
Renko Chart Patterns Made Easy
By — Kaushik Akiwatkar, Derivative Trader and Investor
Stock Trading
Candlesticks Made Easy: Candlestick Pattern Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Dow Theory Made Easy
By — Vishal Mehta, Independent Systematic Trader
Stock Trading
Market 101: An Insight
